Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

91.19 -0.38 (-0.41%)
Streaming Delayed Price Updated: 3:45 PM EST, Jan 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
74 75 Next >
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
UK Drug Pricing Talks Collapse, Drugmakers Reject Offer Citing 'Uncompetitive' System ↗
UK drug pricing talks collapsed after the government and pharma firms failed to agree on National Health Service rebates. 
Via Benzinga
News headline image
J&J Commits $2 Billion To US Manufacturing Expansion Amid Threat Of Drug Tariffs ↗
Johnson & Johnson (NYSE: JNJ) is set to invest $2 billion in its North Carolina facilities, expanding its U.S. manufacturing operations. This move comes in response to potential drug import tariffs... 
Via Benzinga
Topics Government World Trade
News headline image
IonQ Expands Quantum IP Portfolio, Surpassing 1,000 Patents And Applications ↗
IonQ, Inc. announces major progress in its IP strategy with new U.S. patents, reinforcing its leadership in quantum computing and potential for commercial advantage. 
Via Benzinga
Topics Intellectual Property
Fibrogen Gets Regulator’s Green Light To Sell China Unit To AstraZeneca ↗
Via Stocktwits
AstraZeneca CEO Calls US Drug Pricing Model ‘Unsustainable’ — Pushes for Global Rate Alignment ↗
Via Stocktwits
AstraZeneca Q2 Beats On Cancer Drug Sales, Maintains Guidance — Shares Rise Premarket As Retail Cheers ↗
Via Stocktwits
News headline image
AstraZeneca Launches Home Delivery Service For Its Self-Administrable Flu Vaccine ↗
Flumist can be self-administered by adults 18 to 49 years of age or administered by a parent or caregiver to individuals 2-17 years of age. 
Via Stocktwits
News headline image
FLUMIST (Influenza, Vaccine Live, Intranasal), the nation’s only nasal spray flu vaccine, now available for home delivery
From AstraZeneca
Via Business Wire
News headline image
White House Eyes Up to 250% Drug Tariffs In Bid To Reclaim US Pharma Supply Chain ↗
White House trade adviser Peter Navarro discusses tariffs on pharma imports under a "Section 232" trade investigation. 
Via Benzinga
Topics World Trade
News headline image
The Specter of Stagflation: Trump's Tariffs Cast a Long Shadow Over the U.S. Economy
Economists and investors are increasingly sounding the alarm over the growing risk of "stagflation," a perilous economic phenomenon characterized by high inflation coupled with stagnant economic... 
Via MarketMinute
Topics Economy Government Supply Chain
News headline image
Earnings Scheduled For July 29, 2025 ↗
 
Via Benzinga
News headline image
Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca Face Renewed Claims Of Conspiring To Restrict 340B Discounts ↗
A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict 340B drug discounts for safety-net clinics, sending the case back to... 
Via Benzinga
Topics Lawsuit
News headline image
Stagflation Specter Haunts Markets as Economic Data Disappoints
The global financial markets are grappling with a growing sense of unease as recent economic data points to a troubling confluence of high inflation and sluggish growth, rekindling fears of... 
Via MarketMinute
Topics Economy Stocks World Trade
News headline image
1 Small-Cap Biotech Stock Poised for a Breakout ↗
This developmental biotech is nearing a key inflection point. 
Via The Motley Fool
Topics Economy
News headline image
AstraZeneca Earnings Preview ↗
 
Via Benzinga
Moderna, Pfizer, Sanofi In Focus As US Winds Down mRNA Vaccine Plans; Retail Turns Bearish On AstraZeneca ↗
Via Stocktwits
News headline image
EXCLUSIVE: Vivani Prioritizes Semaglutide-Based Implant After Promising Preclinical Data ↗
Vivani reported Phase 1 success for its exenatide implant and shared preclinical semaglutide data showing 231-day weight loss from a single dose. 
Via Benzinga
News headline image
Trump Issues 60 Day Ultimatum To US Pharma Giants To Slash Drug Prices: 'If You Refuse To Step Up We Will...' ↗
President Donald Trump has issued a 60-day ultimatum to 17 major pharmaceutical companies, demanding that they lower drug prices in the U.S. or face severe consequences. 
Via Benzinga
Topics Government
Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch ↗
Via Stocktwits
Topics Government
News headline image
Why AstraZeneca Stock Was Topping the Market on Tuesday ↗
Investors were clearly impressed by the company's second-quarter beats, especially the one on the bottom line. 
Via The Motley Fool
News headline image
AstraZeneca Q2 Sales Beat Estimates On Strong Cancer Drugs Revenues, Reaffirms 2025 Outlook ↗
AstraZeneca posted $14.46 billion in Q2 revenue, reaffirming its 2025 outlook as the FDA advances Imfinzi in gastric cancer. 
Via Benzinga
Topics Earnings
News headline image
AstraZeneca results: H1 and Q2 2025
From AstraZeneca
Via Business Wire
News headline image
Why Is Micro-Cap AIM ImmunoTech Stock Surging? ↗
AIM ImmunoTech shares rise after DURIPANC trial data show superior survival and safety in metastatic pancreatic cancer patients. 
Via Benzinga
News headline image
IMFINZI® (durvalumab) granted Priority Review and Breakthrough Therapy Designation in the US for patients with resectable early-stage gastric and gastroesophageal junction cancers
From AstraZeneca
Via Business Wire
News headline image
5 Dividend Stocks to Hold for the Next 20 Years ↗
Discover five unstoppable dividend stocks that could pay you for life, and why I wouldn't sell any of them! 
Via The Motley Fool
News headline image
AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate ↗
AstraZeneca's gefurulimab showed clinical benefits and favorable safety in Phase 3 trial for adults with anti-AChR antibody-positive gMG. 
Via Benzinga
News headline image
What's Driving the Market Sentiment Around AstraZeneca? ↗
 
Via Benzinga
News headline image
Trump Tariffs Forces AstraZeneca To Bring Substantial Pharmaceutical Production To US ↗
AstraZeneca plans a $50 billion investment in U.S. facilities by 2030, including a Virginia plant focused on weight loss and metabolic drugs. 
Via Benzinga
Topics Government
News headline image
Sanofi Expands Respiratory Vaccine Portfolio With UK Biotech Buy ↗
Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its respiratory vaccine pipeline. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
74 75 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.